Funds and ETFs Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 25/06/2024 BST 5-day change 1st Jan Change
69.61 USD -1.58% Intraday chart for Gilead Sciences, Inc. +8.31% -14.07%

ETFs positioned on Gilead Sciences, Inc.

Name Weight AuM 1st Jan change Investor Rating
13.99% 208 M€ +16.46% -
8.10% 0 M€ 0.00% -
8.06% 0 M€ 0.00% -
5.23% 2 M€ -.--%
3.80% 7 M€ -.--% -
3.55% 1 M€ +2.82% -
2.90% 544 M€ -1.32%
2.66% 21 M€ +9.30% -
2.62% 408 M€ +2.64%
2.58% 7 M€ +6.17% -
2.27% 2 M€ +9.16%
1.67% 1 M€ +2.21% -
1.48% 9 M€ -4.31% -
1.26% 7 M€ +4.63%
1.26% 13,503 M€ +5.38%
1.23% 4,592 M€ -.--%
1.21% 252 M€ +9.30%
1.16% 108 M€ +13.12%
1.04% 779 M€ +3.96%
1.01% 1,060 M€ +5.33%
1.00% 5 M€ -72.95% -
0.98% 3 M€ 0.00% -
0.96% 2 M€ +20.44% -
0.95% 9 M€ -.--% -
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.61 USD
Average target price
82.97 USD
Spread / Average Target
+19.19%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Funds and ETFs Gilead Sciences, Inc.